Back to your search result

Description

A cell-permeable, non-toxic, dihydropyrimidine compound that prevents cellular glycosylation and surface expression of Notch, APP, Klotho (Effect. conc. = 10 µ,M in HEK293, HeLa, U2OS cultures) in a rapid and reversible manner by blocking events prior to cargo assembly at the ER exit sites (ERES) without affecting other post-ERES events targeted by BFA, GCA, Exo1, A5, Retro-2, U18666A, or Vacuolin-1 (Cat. nos. 203729, 345862, 341220, 444805, 554715, 662015, & 673000, respectively). Notch signaling is shown to be effectively inhibited by treatment with either FLI-06 or the gamma-Secretase inhibitior DAPT (Cat. nos. 565770 & 565784) in both C2C12 cultures (10 µ,M FLI-06) in vitro and in zebrafish embryos (50 µ,M FLI-06) in vivo., A cell-permeable, non-toxic, dihydropyridine compound that prevents cellular maturation/glycosylation and surface expression of Notch, APP, Klotho (Effect. conc. = 10 µ,M in HEK293, HeLa, U2OS cultures) in a rapid and reversible manner by blocking events prior to cargo assembly at the endoplasmic reticulum exit sites (ERES) without affecting cytoskeleton, endocytosis, or other post-ERES events targeted by BFA, GCA, Exo1, A5, Retro-2, U18666A, or Vacuolin-1 (Cat. nos. 203729, 345862, 341220, 444805, 554715, 662015, & 673000, respectively). Notch signaling is shown to be effectively inhibited by treatment with either FLI-06 or the gamma-Secretase inhibitior DAPT (Cat. nos. 565770 & 565784) in both C2C12 cultures (10 µ,M FLI-06) in vitro and in zebrafish embryos (50 µ,M FLI-06) in vivo.